Company news
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A (SSE:600276) news
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A news releases on 6ix. Latest, Sep 5, 2025: Hengrui Pharma and Braveheart Bio Enter Exclusive License…
Press releases — page 2
Hengrui Pharma and Braveheart Bio Enter Exclusive License Agreement for Cardiac Myosin Inhibitor HRS-1893
September 5, 2025
Jiangsu Hengrui Medicine : Hengrui Pharma Has Announced its Record-breaking First-half 2025 Results
August 20, 2025
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
July 29, 2025
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
July 26, 2025
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
July 22, 2025
Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
July 15, 2025
Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD
July 8, 2025
Jiangsu Hengrui Medicine : Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR Annual Meeting 2023
April 10, 2023